EXS4318
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
EXS4318 is a selective PKC theta inhibitor that is potentially first-in-class medication. Developed by Exscientia, it was licensed to Bristol Myers Squibb. In 2023, it entered clinical trials in humans.
EXS4318 is a selective PKC theta inhibitor that is potentially first-in-class medication. Developed by Exscientia, it was licensed to Bristol Myers Squibb. In 2023, it entered clinical trials in humans.
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1317176394 under CC BY-SA 4.0; modifications have been made.